| Literature DB >> 29439425 |
Virtudes Pérez-Jover1, José J Mira2,3, Concepción Carratala-Munuera4, Vicente F Gil-Guillen5, Josep Basora6, Adriana López-Pineda7, Domingo Orozco-Beltrán8.
Abstract
The growth of the aging population leads to the increase of chronic diseases, of the burden of multimorbility, and of the complexity polypharmacy. The prevalence of medication errors rises in patients with polypharmacy in primary care, and this is a major concern to healthcare systems. This study reviews the published literature on the inappropriate use of medicines in order to articulate recommendations on how to reduce it in chronic patients, particularly in those who are elderly, polymedicated, or multipathological. A systematic review of articles published from January 2000 to October 2015 was performed using MEDLINE, EMBASE, PsychInfo, Scopus, The Cochrane Library, and Index Medicus databases. We selected 80 studies in order to analyse the content that addressed the question under consideration. Our literature review found that half of patients know what their prescribed treatment is; that most of elderly people take five or more medications a day; that in elderly, polymedicated people, the probability of a medication error occurring is higher; that new tools have been recently developed to reduce errors; that elderly patients can understand written information but the presentation and format is an important factor; and that a high percentage of patients have remaining doubts after their visit. Thus, strategies based on the evidence should be applied in order to reduce medication errors.Entities:
Keywords: chronic disease; medication errors; patient medication knowledge; patient safety; physicians; polypharmacy; primary care
Mesh:
Year: 2018 PMID: 29439425 PMCID: PMC5858379 DOI: 10.3390/ijerph15020310
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1PRISMA flow diagram.
Main topic, country, and evidence level of the reviewed research studies.
| Main Topic ( | Country ( | Evidence Levels * ( |
|---|---|---|
| Adverse Drugs Events (7) | Canada (1) | |
| Italy (1) | 2++ B (2) | |
| United Kingdom (1) | 2+ C (4) | |
| USA (2) | ||
| Spain (2) | ||
| Medication Adherence and Misuse (12) | Austria (1) | 2++ B (2) |
| Canada (1) | 2+ B (1) | |
| Germany (1) | 2+ C (6) | |
| Spain (4) | 2− C (1) | |
| The Netherlands (1) | 4 D (2) | |
| USA (4) | ||
| Medication Errors (13) | Austria (1) | 2++ B (3) |
| Ireland (1) | 2+ B (1) | |
| Israel (1) | 2+ C (6) | |
| United Kingdom (1) | 2− C (2) | |
| USA (2) | 3 D (1) | |
| Spain (6) | ||
| Sweden (1) | ||
| Medication Management (12) | Australia (2) | 1− B (1) |
| USA (3) | 2+ B (1) | |
| Spain (6) | 2+ C (6) | |
| Tokyo (1) | 2− C (2) | |
| 4 D (2) | ||
| Medication Safety Information (20) | Australia (1) | 4 D (6) |
| Canada (2) | 2++ B (2) | |
| United Kingdom (7) | 2+ B (2) | |
| USA (5) | 2+ C (5) | |
| Spain (5) | 2− C (5) | |
| Medication Safety Tools (9) | Norway (1) | 2++ B (1) |
| USA (3) | 2+ C (3) | |
| Spain (2) | 2− C (2) | |
| Taiwan (2) | 3 D (2) | |
| United Kingdom (1) | 4 D (1) | |
| Patient Medication Knowledge (7) | Hong Kong (1) | |
| Spain (2) | 2++ B (2) | |
| Turkey (1) | 2+ C (3) | |
| United Kingdom (1) | 2− C (2) | |
| USA (2) |
* Evidence levels and recommendation grades according to the Scottish Intercollegiate Guidelines Network (SIGN) [13]. Levels of evidence: 1++: High quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias. 1+: Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias. 1−: Meta-analyses, systematic reviews, or RCTs with a high risk of bias. 2++: High quality systematic reviews of case control or cohort or studies; high quality case control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal. 2+: Well-conducted case control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal. 2−: Case control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal. 3: Non-analytic studies, e.g., case reports, case series. 4: Expert opinion. Grades of recommendations: (A) At least one meta-analysis, systematic review, or RCT rated as 1++ and directly applicable to the target population; or a body of evidence consisting principally of studies rated as 1+, directly applicable to the target population, and demonstrating overall consistency of results. (B) A body of evidence including studies rated as 2++, directly applicable to the target population, and demonstrating overall consistency of results; or extrapolated evidence from studies rated as 1++ or 1+. (C) A body of evidence including studies rated as 2+, directly applicable to the target population and demonstrating overall consistency of results; or extrapolated evidence from studies rated as 2++. (D) Evidence level 3 or 4; or extrapolated evidence from studies rated as 2+.